Getting early Parkinson’s psychosis care for your parent

Written by Patricia Weiser, PharmD | Last updated April 6, 2026
Fact-checked by Patrícia Silva, PhD

If your parent is living with Parkinson’s disease, you may eventually notice changes that go beyond symptoms that affect mobility. Some patients begin to see, hear, or sense things that others do not. These experiences can be part of Parkinson’s psychosis.

These symptoms are more common than many families realize. Research suggests that 20% to 40% of people with the disease experience hallucinations or delusions. Recognizing these signs early and discussing them with your parent’s care team can help guide care decisions.

Signs to watch for in your parent

Spotting early Parkinson’s psychosis symptoms may be difficult because they are often subtle and may be mistaken for normal aging or fatigue. Your parent may also feel embarrassed or unsure about how to talk about what they are experiencing.

While symptoms can look different from person to person, Parkinson’s psychosis most often appears as hallucinations, illusions, or delusions.

Hallucinations

Hallucinations in Parkinson’s involve seeing, hearing, or sensing things that are not actually there. Hallucinations may last only seconds or minutes. You might notice your parent:

  • seeing people, animals, or unfamiliar figures
  • hearing voices, music, or knocking that others do not hear
  • talking to relatives, neighbors, or pets that died long ago

Illusions

Illusions are similar to hallucinations but occur when something real is misinterpreted. These experiences can happen when the lighting is dim or when an object is viewed from a distance. Examples of illusions may include mistaking a shadow, a coat rack, or a lamp for a person, or believing someone moved in the room when it was only a shifting shadow.

Autoimmunity and Parkinson’s: Is Parkinson’s Considered an Autoimmune Disease?

Medically reviewed by Heidi Moawad, M.D. — Written by Jill Seladi-Schulman, Ph.D. on May 23, 2023

Parkinson’s disease (PD) is a progressive neurological disorder that affects movement as well as mental and emotional changes. The exact cause is unknown, but researchers are investigating if autoimmune factors may play a role.

PD is a neurological disorder where nerve cells in your brain become damaged or begin to die. While the cause of PD is unknown, there’s evidence that the immune system might be involved.

Below, we’ll cover more about PD and how autoimmune activity could contribute to it. Keep reading to learn more.

What is an autoimmune disease?

Autoimmune diseases happen when your immune system mistakenly attacks healthy tissues. This can cause inflammation and tissue damage in the affected areas of your body.

There are many different types of autoimmune diseases. Some that you may be familiar with include:

  • lupus
  • rheumatoid arthritis
  • psoriasis
  • type 1 diabetes
  • multiple sclerosis

Is Parkinson’s disease considered an autoimmune disease?

The exact cause of PD is unknown, and it’s currently not considered an autoimmune disease. While there’s some evidence that immune factors might be associated with PD, there’s no evidence so far that these immune factors actually cause PD.

A 2017 study found that PD may have genetic factors in common with some autoimmune diseases such as diabetes, ulcerative colitis, rheumatoid arthritis, and others.

What is Pump-Delivered Therapy for Parkinson’s Disease?

Medically reviewed by Susan W. Lee, DO — Written by The Healthline Editorial Team — Updated on July 22, 2025

Pump delivered therapy can help some people ease their Parkinson’s symptoms, especially when a type of medications begins to wear off and symptoms worsen or reappear.

A longtime dream for many living with Parkinson’s disease has been to reduce the number of daily pills or injections needed to manage symptoms. The more the disease progresses, the trickier it can become to manage symptoms.

Pump infusion therapy is becoming a new way to manage certain medications, particularly those to help with OFF episodes when Parkinson’s symptoms may reappear or get worse if a medication is wearing off.

 

Since October 2024, the Food and Drug Administration (FDA) has approved for the first time 2 new devices that can be continuously worn on the body and offer a steady stream of Parkinson’s medications into your bloodstream. Think of these like insulin pumps for people with diabetes, who use these small wearable devices to get their needed insulin continuously throughout the day and night.

 

This type of technology can make it more manageable in the face of changing Parkinson’s symptoms, possibly reducing the amount of medications or injections needed to manage symptoms and the disease overall.

New research shows Parkinson’s off episodes go beyond movement issues

Review identifies 132 areas of impact, including quality of life and fatigue

Written by Andrea Labo | Parkinson's News Today | 

  • Parkinson's off episodes cause 132 impacts, a review found, including non-motor symptoms.
  • These episodes significantly impair quality of life, extending beyond visible movement problems.
  • Inbrija offers rapid motor improvement for off episodes, with good tolerability, data show.

A comprehensive review of the scientific literature identified more than 100 distinct ways in which off episodes affect people with Parkinson’s disease, highlighting a multifaceted burden that extends beyond movement symptoms to include cognitive, emotional, and quality-of-life impacts.

The research was presented by Merz Therapeutics, the company that markets Inbrija (levodopa inhalation powder), at the World Parkinson Congress 2026, held last month in Phoenix.

The findings showed that often overlooked nonmotor symptoms such as fatigue, memory difficulties, and anxiety can be as disruptive as physical symptoms during off episodes — periods when symptoms return in between medication doses — underscoring the need for treatment approaches that address the full patient experience.

The company also presented additional analysis from three Phase 3 trials confirming the safety and efficacy of Inbrija (levodopa inhalation powder) in providing consistent and rapid motor improvement for patients experiencing off episodes.

“For too long, the conversation around ‘off’ episodes has focused primarily on visible motor symptoms. Our research highlights what we’ve been hearing from people with Parkinson’s: the burden of an ‘off’ episode is far broader and more disruptive than what can be seen,” Stefan Albrecht, MD, PhD, Merz’s chief scientific and medical officer, said in a company press release. “It is a call to action for the entire Parkinson’s community to recognize and address the significant impact of ‘off’ episodes.”

How walking poles can benefit those of us with Parkinson’s disease

I may have found the perfect exercise

Written by Christine Scheer | Parkinson's News Today | 

For me, having goals is very important. For instance, in the 5K race that I ran last weekend, my goal was to smile for the last 100 meters or so, because that is when they snap a photo of you. Does it matter that I came in 1,153rd? No, it does not, because I had a smile on my face and the photo to prove it!

About four months ago, someone sent me a social media post about a Parkinson’s walking group. This group looked like a happening place; they used walking poles, had a walking coach, and were enjoying all the benefits of walking, getting outside, and camaraderie. I instantly wanted to be a part of it, but it was somewhere in the U.S., so this Canadian gal needed a local solution.

The more I read about pole walking, the more I wanted to be part of a similar group. The benefits are innumerable for people with Parkinson’s. According to the Parkinson’s Foundation, using poles can promote larger, more symmetrical movements, improve balance, correct posture, and increase stride length, ultimately helping to reduce the shuffling gait common in those with the condition.

Not only are the physical benefits of pole walking astounding, but the psychological benefits are fantastic as well. Increased confidence, improved mood, and social connection are all on the table. It seems like the perfect exercise routine.

Continue Reading Here

Gut bacteria transplant may ease constipation in Parkinson’s

Evidence for motor and nonmotor benefits remains limited, researchers say

Written by Lila Levinson, PhD | June 10, 2026

  • Fecal microbiota transplantation (FMT) shows promise for Parkinson’s-related constipation.
  • FMT was generally safe and beneficial for gastrointestinal symptoms in people with Parkinson’s.
  • Evidence for broader motor and nonmotor benefits is inconsistent, and more high-quality research is needed.

Fecal microbiota transplantation (FMT), a technique for replacing gut bacteria, may help with gastrointestinal symptoms of Parkinson’s disease, particularly constipation, according to a review study.

While the technique was found to be generally safe and beneficial for gastrointestinal symptoms in Parkinson’s disease, “at this stage, there is no convincing evidence that FMT produces a clinically relevant motor or non-motor symptomatic improvement on a group basis, at least in the short to medium term,” the researchers wrote.

Evidence on FMT remains limited

The researchers noted that available studies about FMT in Parkinson’s use a variety of different techniques, and many have methodological limitations. Future high-quality research could help clarify the potential benefits of FMT in this context.

The study, “Safety and efficacy of faecal microbiota transplantation in Parkinson’s disease,” was published in npj Parkinson’s Disease.

Parkinson’s is a neurological condition that leads to a variety of motor and nonmotor symptoms. Constipation and other gastrointestinal problems are among the possible nonmotor signs of the condition.

Parkinson’s and the digestive tract have a complex relationship. Not only can Parkinson’s cause gastrointestinal symptoms, but the bacteria and other microorganisms living in the intestines, collectively known as the gut microbiota, may influence certain disease processes. For example, the review noted that animal studies suggest that gut microbiota from people with Parkinson’s may promote inflammation and nerve degeneration.

These connections have led scientists to wonder whether altering the gut microbiota could be used as a treatment strategy for Parkinson’s. One way to do this is with FMT, which the researchers described as “an ultimate treatment for replacing the host microbiota with that of a healthy donor.”

There are several methods for performing FMT. Typically, they involve first collecting gut bacteria from donors’ stool. Patients receive the transplant as a capsule, an enema (a liquid placed into the rectum), or a procedure delivering the sample directly to the digestive system.

The team aimed to comprehensively examine existing research about FMT in Parkinson’s, which remains limited. “This review examines the current evidence on FMT in [Parkinson’s disease] concerning safety, efficacy, and microbiome changes, and analyses the data in the perspective of recommendations for future studies in this field,” they wrote.